About this trial
To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage.
There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage.
Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage.
Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).
Eligibility criteria
Qualifiers
None
Disqualifiers
Women under 18 years old
Women with known coagulation disorders
Women with planned cesarean hysterectomy
Women with known placental accreta spectrum disorders
Trial design
Treatments tested in this trial
- Sublingual Misoprostol
- IV Oxytocin